No further internal development will be done on ABI-4344, ASMB’s fourth(!) HBV core inhibitor. ASMB dumped its third HBV core inhibitor, ABI-H3733, a few weeks ago and has yet to do anything right in HBV (see #msg-171513883 and the embedded links there).
According to today’s PR, ASMB’s clinical focus will now be its herpes and HDV programs.